New drug may help Hard-to-Transplant kidney patients stay off dialysis longer

NCT ID NCT05714514

Ongoing Disease control Sponsor: Hansa Biopharma AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 64 highly sensitized kidney transplant patients who previously received either imlifidase or standard care in an earlier trial. Researchers will track how many patients are alive and free of dialysis at 3 and 5 years, as well as graft survival. The goal is to see if imlifidase helps these hard-to-match patients achieve better long-term transplant success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imlifidase
What this could lead to: If successful, this could show that imlifidase helps highly sensitized patients receive a kidney transplant and maintain good long-term outcomes.
What could go wrong: This is a small follow-up study (64 patients) with no new treatment, so results may not apply broadly. Long-term risks like graft rejection or side effects remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS

Contacts and locations

Locations

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Columbia University

New York, New York, 10032, United States
Cooperman Barnabas Medical Center

Livingston, New Jersey, 07039, United States
Houston Methodist Hospital

Houston, Texas, 77030, United States
John Hopkins Hospital

Baltimore, Maryland, 21287, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Methodist Hospital Specialty and Transplant

San Antonio, Texas, 78229, United States
New York University (NYU) Langone Transplant Institute, NYU Langone Health

New York, New York, 10016, United States
Northwestern University, Dept. General Surgery, Div. Transplantation

Chicago, Illinois, 60611, United States
University of Alabama at Birmingham (UAB) Hospital

Birmingham, Alabama, 35249, United States
University of Chicago, Department of Surgery, Clinical Research Center

Chicago, Illinois, 60637, United States
University of Washington Medical Center

Seattle, Washington, 98195, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.